STAAR Surgical Company reaffirmed sales guidance for the year 2022. For the year, the company reaffirming previously provided outlook for fiscal 2022 net sales of approximately $295 million, which takes into account a significant currency headwind and a continuation of the current level of COVID-19 related challenges in China and elsewhere, offset by stronger than expected demand for EVO lenses, which has continued through the beginning of the third quarter.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
40.34 USD | +0.51% | -3.53% | +30.34% |
05-08 | Mizuho Adjusts STAAR Surgical's Price Target to $55 From $53, Keeps Buy Rating | MT |
05-08 | Morgan Stanley Raises Price Target on STAAR Surgical to $50 From $35, Keeps Equalweight Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+30.34% | 1.97B | |
-7.42% | 175B | |
-1.99% | 107B | |
-7.37% | 65.05B | |
-3.07% | 50.76B | |
+7.59% | 43.14B | |
+5.93% | 41.46B | |
+14.52% | 30.69B | |
+13.37% | 25.39B | |
-5.80% | 23.69B |
- Stock Market
- Equities
- STAA Stock
- News STAAR Surgical Company
- STAAR Surgical Company Re-Affirms Sales Guidance for the Year 2022